ARTL (Artelo Biosciences) Total Assets: $12.52 Mil (As of Mar. 2026)


ARTL Artelo Biosciences Inc ARTL
31 GF Score
Price $1.13
! 2 Warning Signs
View Full Analysis

What is Artelo Biosciences Total Assets?

Artelo Biosciences ARTL -1.75% 31 Total Assets is $12.52 Mil as of Mar. 2026. GuruFocus rates ARTL with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Artelo Biosciences's Total Assets for the quarter that ended in Mar. 2026 was $12.52 Mil.

During the past 12 months, Artelo Biosciences's average Total Assets Growth Rate was -6.70% per year. During the past 3 years, the average Total Assets Growth Rate was -8.70% per year. During the past 5 years, the average Total Assets Growth Rate was -1.20% per year.

During the past 12 years, Artelo Biosciences's highest 3-Year average Total Assets Growth Rate was 1207.30%. The lowest was -8.70%. And the median was 8.70%.

Total Assets is connected with ROA %. Artelo Biosciences's annualized ROA % for the quarter that ended in Mar. 2026 was -154.47%. Total Assets is also linked to Revenue through Asset Turnover. Artelo Biosciences's Asset Turnover for the quarter that ended in Mar. 2026 was 0.00.

Artelo Biosciences  (NAS:ARTL) Total Assets Explanation

Total Assets is connected with ROA %.

Artelo Biosciences's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-11.832/( (2.801+12.518)/ 2 )
=-11.832/7.6595
=-154.47 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Artelo Biosciences's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0/( (2.801+12.518)/ 2 )
=0/7.6595
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Artelo Biosciences Total Assets Related Terms

Artelo Biosciences Total Assets Historical Data

* Premium members only.

The historical data trend for Artelo Biosciences's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Artelo Biosciences Total Assets Chart

Artelo Biosciences Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.64 20.42 13.04 4.70 2.80

Artelo Biosciences Quarterly Data
May21 Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.52 4.36 4.27 2.80 12.52
ARTL
31GF Score
Artelo Biosciences Inc ARTL
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Artelo Biosciences Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Artelo Biosciences's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=-1.272+4.073
=2.80

Artelo Biosciences's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=6.672+5.846
=12.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $12.52 Mil mean?
Artelo Biosciences (ARTL) has a Total Assets of $12.52 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Artelo Biosciences and its competitors.
Is Artelo Biosciences' Total Assets too high?
Artelo Biosciences' current Total Assets is $12.52 Mil. Overall, Artelo Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Artelo Biosciences' Total Assets compare to RNAZ and GLMD?
Artelo Biosciences' Total Assets of $12.52 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Artelo Biosciences and its competitors. Artelo Biosciences's current Total Assets is $12.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artelo Biosciences stock overvalued right now?
Artelo Biosciences (ARTL) has a current Total Assets of $12.52 Mil. The current Total Assets is $12.52 Mil. Artelo Biosciences' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Artelo Biosciences (ARTL), the current Total Assets is $12.52 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Artelo Biosciences Business Description

Address 505 Lomas Santa Fe, Suite 160, Solana Beach, CA, USA, 92075
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
31GF Score

Get the complete analysis for ARTL

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.13
Price